FDA Approves Cathflo Activase
SOUTH SAN FRANCISCO, Calif-The US Food and Drug Administration (FDA) has approved Cathflo Activase (Alteplase) for the restoration of function to central venous access devices (CDADs) that have become occluded by a blood clot, or thrombus.
Cathflo Activase is a thrombolytic agent that works by targeting substances that cause blood to clot. The device dissolves the clot and restores function to the CVAD. This is the first thrombolytic agent approved by the FDA for this purpose.
CVADs, a broad term that includes many types of catheters, are used to withdraw blood or administer medications and nutritional fluids to critically ill patients. There are an estimated 5 million catheters used in US hospitals annually, with 25% of these estimated to become blocked.
Cathflo Activase works by activating plasminogen that dissolves fibrin-a substance that causes blood to clot. This process breaks down the thrombus and leaves the CVAD functioning properly.
FDA approval of the device is based on two Phase III clinical trials that tested safety and efficacy in the restoration of CVAD function during the process.
The device has been created by Genetch, Inc., based in South San Francisco, California.
For more information about the company, log onto www.gene.com
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
